Please use this identifier to cite or link to this item: http://earsiv.odu.edu.tr:8080/xmlui/handle/11489/4983
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAkyol, A.-
dc.contributor.authorYuman, M.-
dc.contributor.authorSabin, M.-
dc.contributor.authorSimsek, H.-
dc.contributor.authorAkdag, S.-
dc.contributor.authorGumrukcuoglu, H. A.-
dc.contributor.authorGuler, A.-
dc.contributor.authorOzturk, F.-
dc.contributor.authorGumrukcuoglu, F. Nur-
dc.contributor.authorTuncer, M.-
dc.date.accessioned2024-03-26T06:21:38Z-
dc.date.available2024-03-26T06:21:38Z-
dc.date.issued2018-
dc.identifier.citationAkyol, A., Yuman, M., Sabin, M., Simsek, H., Akdag, S., Gümrükçüoglu, HA., Güler, A., Öztürk, F., Gümrükçüoglu, FN., Tuncer, M. (2018). Maternal, fetal outcome, and anticoagulant management in pregnant women with prosthetic heart valves. Clin. Exp. Obstet. Gynecol., 45(2), 218-223. https://doi.org/10.12891/ceog3818.2018en_US
dc.identifier.issn0390-6663-
dc.identifier.issn2709-0094-
dc.identifier.urihttp://dx.doi.org/10.12891/ceog3818.2018-
dc.identifier.urihttps://www.webofscience.com/wos/woscc/full-record/WOS:000435158400016-
dc.identifier.urihttp://earsiv.odu.edu.tr:8080/xmlui/handle/11489/4983-
dc.descriptionWoS Categories: Obstetrics & Gynecologyen_US
dc.descriptionWeb of Science Index: Science Citation Index Expanded (SCI-EXPANDED)en_US
dc.descriptionResearch Areas: Obstetrics & Gynecologyen_US
dc.description.abstractIntroduction: Cardiac disease in maternity is a great problem particularly in developing countries. Pregnant patients with prosthetic heart valves (PHV) may suffer therapeutic difficulty, as the need for anticoagulation is fraught with risk of hemorrhagic or thromboembolic complications and structural valve deterioration. The present study aimed to evaluate the maternal, fetal outcome, and anticoagulant management in pregnant women with PHV. Materials and Methods: This study is prospective observational research. The medical archives of pregnant patients with PHV from September 2010 to January 2015 were scanned. Data collected from Yuzuncu Yil University Hospital Cardiology clinics archives included demographic characteristics, anticoagulant, presence or absence of obstructive or non-obstructive thrombus, and maternal-fetal outcome. Results: The authors evaluated the outcomes of 56 pregnant patients with PHV. The age at the time of pregnancy ranged between 19 and 37 (mean 28.7 +/- 8.4) years. Most common preferred anticoagulation therapy was heparin during the first trimester, followed by oral anticoagulation up to the 36th week, with subsequent replacement by heparin until delivery. Most common encountered complication was preterm birth. Death occurred in one patient due to obstructive valve thrombosis. Conclusion: Ideal PHV is not accessible for women during childbearing age. The risk of adverse event during pregnancy depends on valve position, symptoms, valve type, cardiac function, and functional capacity in patients with PHV. The active collaboration among an obstetrician, a cardiologist, and a cardiothoracic surgeon is required for optimal outcome patient with PHV.en_US
dc.language.isoengen_US
dc.publisherIMR PRESS-ROBINSONen_US
dc.relation.isversionof10.12891/ceog3818.2018en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPregnancy, Prosthetic heart valve, Anticoagulationen_US
dc.subjectLONG-TERM SURVIVAL, YOUNG-WOMEN, COMPLICATIONS, REPLACEMENTen_US
dc.titleMaternal, fetal outcome, and anticoagulant management in pregnant women with prosthetic heart valvesen_US
dc.typearticleen_US
dc.relation.journalCLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGYen_US
dc.contributor.departmentOrdu Üniversitesien_US
dc.identifier.volume45en_US
dc.identifier.issue2en_US
dc.identifier.startpage218en_US
dc.identifier.endpage223en_US
Appears in Collections:Dahili Tıp Bilimleri

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.